Fly News Breaks for December 2, 2019
Dec 2, 2019 | 13:48 EDT
JMP Securities analyst Jason Butler reiterates an Outperform rating on Aquestive Therapeutics with a $23 price target after the company announced this morning that the final component of the rolling New Drug Application filing for Libervant has been completed. This is a positive sign of management's execution, says Butler, who looks forward to a likely 2020 launch of Libervant.
News For AQST From the Last 2 Days
There are no results for your query AQST